Get the Stockscreener App
10.46
4.08%
0.41
After Hours:
10.40
-0.06
-0.57%
Vir Biotechnology Inc stock is traded at $10.46, with a volume of 2.24M.
It is up +4.08% in the last 24 hours and up +12.96% over the past month.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
See More
Previous Close:
$10.05
Open:
$10
24h Volume:
2.24M
Relative Volume:
0.68
Market Cap:
$1.67B
Revenue:
$68.56M
Net Income/Loss:
$-437.99M
P/E Ratio:
-3.306
EPS:
-3.1639
Net Cash Flow:
$-396.61M
1W Performance:
+9.87%
1M Performance:
+12.96%
6M Performance:
+72.32%
1Y Performance:
+86.12%
1-Day Range:
$9.95
$10.47
1-Week Range:
$9.06
$10.47
52-Week Range:
$4.155
$10.94
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology Inc
Sector
Industry
Phone
415-906-4324
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
10.46 | 1.61B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-03-25 | Initiated | Evercore ISI | Outperform |
| Aug-27-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-29-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-23 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-21-23 | Upgrade | Goldman | Neutral → Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-14-22 | Initiated | SVB Leerink | Outperform |
| Sep-09-22 | Initiated | Morgan Stanley | Underweight |
| Mar-03-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Dec-21-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Oct-25-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Jan-27-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Sep-14-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-11-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-20-20 | Initiated | Needham | Buy |
| Mar-19-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-13-20 | Downgrade | Goldman | Buy → Neutral |
| Feb-27-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Feb-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-19 | Initiated | Robert W. Baird | Neutral |
| Nov-05-19 | Initiated | Barclays | Overweight |
| Nov-05-19 | Initiated | Cowen | Outperform |
| Nov-05-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | JP Morgan | Overweight |
View All
Vir Biotechnology Inc Stock (VIR) Latest News
Vir Biotechnology Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Vir Biotechnology Rings the Closing Bell - Nasdaq
A Look At Vir Biotechnology (VIR) Valuation After New VIR-5500 Prostate Cancer Trial Milestone - Yahoo Finance
VIR SEC FilingsVir Biotechnology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer - BioSpace
Vir Biotechnology Q1 2025 Earnings Preview - MSN
Vir Biotechnology doses first patient in VIR-5500 expansion trial By Investing.com - Investing.com Australia
Vir Biotechnology (VIR) Advances Phase 1 Trial with First Patien - GuruFocus
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-ta - PharmiWeb.com
Vir Biotechnology doses first patient in VIR-5500 expansion trial - Investing.com
Vir Biotech CEO Stock Sale: $664K Transaction in April 2026News and Statistics - IndexBox
Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000 - The Motley Fool
Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000 - The Motley Fool
VIR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Vir Biotechnology Announces Upcoming Chief Medical Officer Transition - TipRanks
Vir Biotechnology (NASDAQ: VIR) Chief Medical Officer to step down April 24 - Stock Titan
Quarterly Risk: Can Vir Biotechnology Inc be recession proof2026 Outlook & Weekly High Return Opportunities - baoquankhu1.vn
Vir Biotechnology (VIR) Leading with Its BiTEs Therapy - Insider Monkey
Vir Biotechnology’s CMO Change Already Reflected in Valuation—Attention Shifts to Execution Risks for VIR-5500 - Bitget
Aberdeen Group plc Sells 135,688 Shares of Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Vir Biotechnology CEO de Backer sells $664k in stock By Investing.com - Investing.com Canada
Vir Biotechnology (NASDAQ:VIR) CEO Backer Marianne De Sells 72,559 Shares - MarketBeat
Vir Biotechnology CEO de Backer sells $664k in stock - Investing.com
Vir Biotechnology (VIR) CEO auto-sells 72,559 shares to cover RSU tax - Stock Titan
VIR Biotechnology Inc (NASDAQ:VIR) Emerges as a High-Growth Momentum Pick - ChartMill
Exit Recap: What is the Moat Score of Vir Biotechnology Inc2026 Bull vs Bear & Weekly Momentum Stock Picks - baoquankhu1.vn
VIR (NASDAQ: VIR) Form 144 shows 72,559-share sale after vesting - Stock Titan
Evercore ISI Group Initiates Coverage of Vir Biotechnology (VIR) with Outperform Recommendation - MSN
VIR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Market Catalysts: Is Vir Biotechnology Inc a good stock for dollar cost averaging2026 Key Highlights & AI Powered Market Trend Analysis - baoquankhu1.vn
Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR) - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Director Sells $199,540.00 in Stock - MarketBeat
Vir Biotechnology director Sato sells $199k in shares By Investing.com - za.investing.com
Vir Biotechnology director Sato sells $199k in shares - Investing.com
Vir Biotechnology (VIR) director sells 22,000 shares in open market - Stock Titan
Vir Biotechnology (VIR) price target increased by 26.10% to 20.74 - MSN
Energy Moves: Is Vir Biotechnology Inc stock a smart retirement pickPortfolio Update Report & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Bull Bear: Is Vir Biotechnology Inc stock heavily shortedNew Guidance & Consistent Growth Stock Picks - baoquankhu1.vn
Investor Mood: How volatile is LGLWS stockWeekly Earnings Recap & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Vir Biotechnology, Inc. (VIR) Stock Forecasts - Yahoo Finance
Why did Vir Biotechnology stock surge 60% after-hours today? - MSN
Vanguard affiliates disaggregate holdings; VIR shows 0% ownership (VIR) - Stock Titan
These analysts boost their forecasts on Vir Biotechnology - msn.com
Vir Biotechnology Inc Stock (VIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):